📖 Read Our In-Depth Guide

Learn about KRAS inhibitors, immunotherapy combinations, PARP inhibitors, and early detection screening for pancreatic cancer.

Pancreatic Cancer Clinical Trials UK (2026) →
ml> Pancreatic Cancer Clinical Trials UK � TrialConnect
Actively Recruiting

Pancreatic Cancer Clinical Trials

Find recruiting clinical trials for pancreatic cancer in the UK � from surgical adjuvant therapy to FOLFIRINOX and targeted treatments. See where trials fit into your treatment pathway.

Free to use � Live data from ClinicalTrials.gov � Updated daily

🎯 Smart Matcher — Find Trials For You

Answer a few questions about your condition and we'll match you to the most relevant clinical trials.

Find My Matches →

Pancreatic Cancer Treatment Pathway

See where clinical trials fit into your treatment journey

Resectable: Surgery + Adjuvant Chemotherapy

For the ~15% diagnosed early enough for surgery, followed by chemotherapy to reduce recurrence risk

Standard: Whipple procedure (pancreaticoduodenectomy) followed by modified FOLFIRINOX or gemcitabine

Borderline Resectable: Neoadjuvant Therapy

Chemotherapy (sometimes with radiation) to shrink the tumour before surgery

Standard: FOLFIRINOX or gemcitabine/nab-paclitaxel for 2-4 months before reassessing for surgery

Locally Advanced: Chemotherapy � Radiation

Tumours that can't be surgically removed but haven't spread distantly

Standard: FOLFIRINOX or gemcitabine/nab-paclitaxel; some centres add stereotactic radiotherapy

Metastatic: Systemic Therapy & Novel Approaches

For widespread disease, trials explore immunotherapy, targeted therapy, and new drug combinations

Emerging: KRAS G12C inhibitors, PARP inhibitors (for BRCA-mutated), immunotherapy combinations, and stroma-modulating agents

About Pancreatic Cancer

What is Pancreatic Cancer?

Pancreatic cancer affects about 10,500 people per year in the UK. It's one of the hardest cancers to treat � only about 25% survive one year and 7% survive five years. Symptoms often appear late: jaundice, back pain, unexplained weight loss, and new-onset diabetes.

Why Trials Matter

Pancreatic cancer has seen the smallest improvement in survival of any cancer over the past 50 years. Only 1 in 10 patients currently joins a trial. New approaches � KRAS-targeted drugs, immunotherapy combinations, and early detection strategies � could transform outcomes.

KRAS & Molecular Profiling

About 90% of pancreatic cancers carry KRAS mutations (most commonly G12D or G12V). New KRAS G12C inhibitors are showing promise in early trials. Molecular profiling of your tumour can identify targeted therapy options � ask your oncologist about genomic testing.

Search Pancreatic Cancer Trials

Loading trials from ClinicalTrials.gov...

Frequently Asked Questions

Active research includes immunotherapy combinations, KRAS G12C inhibitors, stroma-targeting agents, oncolytic viruses, and personalised treatment based on molecular profiling. Several promising approaches are in Phase 3.

Yes. Neoadjuvant trials (treatment before surgery) and adjuvant trials (after surgery) aim to improve cure rates. The ESPAC and POLO trials have changed practice, and newer trials build on these.

The POLO trial showed that Olaparib (a PARP inhibitor) maintenance therapy significantly delays disease progression in BRCA-mutant pancreatic cancer. It established a new treatment paradigm for this subgroup.

How to Join a Pancreatic Cancer Clinical Trial

1

Search

Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.

2

Discuss

Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.

3

Contact

Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.

4

Enrol

If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.

Read Our In-Depth Guide

Learn about KRAS inhibitors, immunotherapy combinations, PARP inhibitors, and early detection screening for pancreatic cancer.

Pancreatic Cancer Clinical Trials UK (2026) →

Related Comparisons

Immunotherapy vs Chemotherapy

Emerging immunotherapy approaches for pancreatic cancer

Targeted Therapy vs Chemotherapy

Precision approaches for pancreatic cancer
🗺️ Related Pathway: Oncology & Cancer Pathway